Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WD-1603 PK study in healthy subjects
NCT04513340Phase 1Unknown
- Sponsor
- Shanghai WD Pharmaceutical Co., Ltd.
- Start
- Aug 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of WD-1603 in Parkinson's disease (PD) (4 arms), sponsored by Shanghai WD Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration at Day 2, Area Under the Curve from time 0 to last measurable concentration at Day 2 and 1 more. Status: unknown.
02
Drugs
WD-1603
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04513340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04513340.